加载中
NASDAQHealthcareMedical - Diagnostics & Research
最新数据
US$167.18
+US$3.005 · +1.83%
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
常规交易时段
US$167.18
+US$3.005 · +1.83%
盘中时间采用ET。市场数据可能有所延迟。
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
日内区间
当前US$167.18
52周区间
当前US$167.18
盘中时间采用ET。市场数据可能有所延迟。
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. The company has a strategic alliance with Advarra, Inc. for the development of a connected, research-ready clinical trial site network model. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
日内区间
当前US$167.18
52周区间
当前US$167.18
近期已公布业绩
近期已公布业绩
| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2008年8月13日 | 2:1 | — | — |
股票拆分 | 2006年10月24日 | 2:1 | — | — |
已生效 2008年8月13日
2:1
已生效 2006年10月24日
2:1
报告持有此股票敞口的交易所交易基金。
U.S. Small Cap Value Portfolio ETF Class SharesDFSV1.2亿0.45%268.09亿 USD0.33%US$38.055+0.28%
Guggenheim Funds Trust - Guggenheim Ultra Short Income ETFGCSH1亿0.21%1.46亿 USD0.25%US$49.854+0.01%
Dimensional - US Targeted Value ETFDFAT3676.82万0.12%301.22亿 USD0.33%US$67.60+0.49%
Principal Exchange-Traded Funds - Principal International Equity ETFPIEQ2602.41万1.96%13亿 USD0.48%US$35.53-0.17%
Dimensional - US Core Equity 2 ETFDFAC2142.93万0.02%885.96亿 USD0.21%US$45.365+0.08%
Dimensional - US Small Cap ETFDFAS2019.45万0.06%338.69亿 USD0.31%US$78.365+0.02%
State Street SPDR Portfolio Developed World ex-US ETFSPDW1605.73万0.04%404.62亿 USD0.03%US$49.725-0.50%
Thrivent Small-Mid Cap Equity ETFTSME1447.93万1.63%8.88亿 USD0.65%US$46.56-0.26%U.S. Small Cap Value Portfolio ETF Class SharesDFSVGuggenheim Funds Trust - Guggenheim Ultra Short Income ETFGCSHDimensional - US Targeted Value ETFDFATPrincipal Exchange-Traded Funds - Principal International Equity ETFPIEQDimensional - US Core Equity 2 ETFDFACDimensional - US Small Cap ETFDFASState Street SPDR Portfolio Developed World ex-US ETFSPDWThrivent Small-Mid Cap Equity ETFTSMEAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
